Bruce W. Konicek

Eli Lilly (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

21h-index3.4kcitations66works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(25), Psoriasis: Treatment and Pathogenesis(13), Cancer Mechanisms and Therapy(12), Prostate Cancer Treatment and Research(7), Polyamine Metabolism and Applications(6)

Publications66 total

Comparative Molecular Analysis of IL-17A and IL-23 Pathway Inhibition in Moderate-to-Severe Psoriasis: 4-Week Results from IXORA-R
Journal of Investigative Dermatology·2025Open Access
Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)
Advances in Therapy·2024· 2 citedOpen Access
Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)
Acta Dermato Venereologica·2024· 6 citedOpen Access
51784 Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)
Journal of the American Academy of Dermatology·2024· 1 cited
51202 Effectiveness of Biologics in Clinical Practice: Interim Month 24 Results from the International Observational Psoriasis Study of Health Outcomes (PSoHO)
Journal of the American Academy of Dermatology·2024Open Access
51582 Simultaneous Genital Skin Clearance and Patient Reported Outcome Responses at Weeks 24 and 52 in Patients with Moderate-to-Severe Genital Psoriasis Treated with Ixekizumab: an analysis of the Phase 3 Clinical Trial IXORA-Q
Journal of the American Academy of Dermatology·2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
Journal of Drugs in Dermatology·2024· 2 cited
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO
Dermatology and Therapy·2024· 4 citedOpen Access
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
Dermatology and Therapy·2024· 3 citedOpen Access
43335 Ixekizumab reduces IL-17 and IL-23 pathway genes more rapidly than guselkumab: 4-week results from IXORA-R
Journal of the American Academy of Dermatology·2023Open Access
Supplementary Table 1 from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
2023Open Access
Supplementary Table 1 from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
2023Open Access
Data from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
2023Open Access
Data from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
2023Open Access
IL17A Blockade with Ixekizumab Suppresses MuvB Signaling in Clinical Psoriasis
Journal of Investigative Dermatology·2023· 5 citedOpen Access
Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry
Journal of Psoriasis and Psoriatic Arthritis·2023· 1 citedOpen Access
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
Dermatology and Therapy·2022· 8 citedOpen Access
25792 Improvements in BSA associate with improvements in itch and quality of life in patients with moderate-to-severe psoriasis treated with ixekizumab or guselkumab through 24 weeks
Journal of the American Academy of Dermatology·2021
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)
Journal of Drugs in Dermatology·2021· 6 cited
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
Oncotarget·2018· 49 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Jeremy R. Graff(28), Ann M. McNulty(15), Blake Lee Neubauer(11), Stephen H. Parsons(11), Rebecca L. Lynch(9), Michele Dowless(8), Louis F. Stancato(8), Julia H. Carter(8), Chad A. Dumstorf(8), Andrew Capen(7), Larry E. Douglass(7), Bruce M. Colligan(7), S. Betty Yan(7), Victoria L. Peek(7), Bernadette M. Hurst(6), James A. Deddens(6), Jennifer R. Stephens(6), Suzane L. Um(6), Richard A. Walgren(6), Robin L. Goode(5)